Stocktoria
ADMA BIOLOGICS, INC. ADMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-10-17
ADMA BIOLOGICS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 57.4% | 51.5% | 34.4% | 22.9% | 1.4% |
| Operating margin | 37.5% | 32.6% | 8.4% | -25.5% | -72.1% |
| Net margin | 28.8% | 46.4% | -10.9% | -42.8% | -88.5% |
| FCF margin | 5.5% | 25.9% | 1.6% | -47.6% | -155.5% |
| Return on assets | 23.5% | 40.5% | -8.6% | -18.9% | -25.9% |
| Return on equity | 30.8% | 56.6% | -20.9% | -43.4% | -50.8% |
| Debt / equity | 0.15× | 0.21× | — | — | — |
| Current ratio | 6.71 | 5.97 | 5.16 | 6.89 | 6.87 |
| Revenue growth | 19.6% | 65.2% | 67.6% | 90.4% | 91.7% |
Source: SEC EDGAR filings · CIK 0001368514 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.